NovaBay Pharmaceuticals (NYSE:NBY) has formally regained compliance with the NYSE American’s continued listing standards, successfully resolving deficiencies first cited in April and May 2024.
The company was previously cited for non-compliance with the NYSE American Company Guide Sections 1003(a)(i), (ii), and (iii), which require